To: John Pitera who wrote (105 ) 12/3/1999 2:12:00 PM From: John Pitera Respond to of 2850
NMPS--Biotech--Cancer Screening-- NMPS will benefit from strategic partnership with Major Drug company/ies, and hires John Doherty, who had a background in negotiating Strategic Relationships and Partnerships . Which is just what NMPS needs. The NMPS Story --------------------- Friday October 8, 9:16 am Eastern Time Company Press Release SOURCE: Matritech, Inc. Matritech Announces Appointment of John S. Doherty, Jr., as Vice President, Finance and Chief Financial Officer Doherty served as Director of Acquisitions and Investments at Digital Equipment Corporation NEWTON, Mass., Oct. 8 /PRNewswire/ -- Matritech, Inc. (Nasdaq: NMPS - news), a company specializing in products designed to manage and screen cancer, announced today that John S. Doherty, Jr., has been appointed to the position of Vice President, Finance and Chief Financial Officer, effective immediately. Doherty replaces Robert W. Morgan.Mr. Doherty spent more than 20 years with Digital Equipment Corporation, much of this time working with emerging technology companies . He held positions including Director of Acquisitions and Investments, Group Controller, Tax Planning Manager and Treasury Manager. Most recently, Mr. Doherty served as Vice President of Corporate Ventures and Taxes at Global Knowledge Network, Inc., the world's largest independent provider of information technology education. Mr. Doherty also worked eight years as a CPA for Peat, Marwick, Mitchell & Co. ``John's experience in negotiating strategic relationships will be invaluable as the Company continues negotiations with marketing partners for the further commercialization of our flagship product, the NMP22© Test Kit for bladder cancer,' said David L. Corbet, President and Chief Operating Officer of Matritech. ``I look forward to joining this management team and assisting Matritech in realizing significant market opportunity for its NMP-based products,' said Mr. Doherty. Matritech's core technology is based on the detection of cancer related nuclear matrix proteins (NMPs) that are detected in body fluids or cells. These levels are correlated to the presence of cancer, even at early stages. The Company is developing and commercializing innovative serum-, cell- and urine-based NMP diagnostics that enable physicians to reliably detect and monitor the presence of bladder, cervical, colon, breast and prostate cancers. The NMP22 Bladder Cancer Test Kit has been cleared by the U.S. FDA for monitoring patients who have previously been treated for bladder cancer, and is under review for testing symptomatic, but previously undiagnosed bladder cancer patients. NMP22 is also approved for detection and management of bladder cancer in China and in Japan. The test is also in use in Europe. In addition to the NMP22 Test Kit, the Company has developed the NMP179(TM) cervical cancer kit, the NuMA(TM) Colon Cancer Test Kit, and has products for breast and prostate cancer under development.